(secondQuint)Safety, Efficacy, and Pharmacokinetics of Amphotericin B Lipid Complex.

 This is a randomized, open label, prospective study of ABLC at 5.

0 and 10.

0 mg/kg/d for treatment of patients with cryptococcal meningitis.

 Patients will be randomly assigned in a 1:1 ratio to receive 5.

0 or 10.

0 mg/kg/d of ABLC as induction therapy for cryptococcal meningitis.

 Patients receiving 10 mg/kg/d doses will be treated with ABLC for 7 days whereas patients receiving ABLC at 5.

0 mg/kg/d will receive 14 days of ABLC therapy.

 After completion of induction therapy subjects will receive long-term fluconazole maintenance therapy at the discretion of the treating physician.

 The study will be conducted at the Washington Hospital Center.

 Safety, Efficacy, and Pharmacokinetics of Amphotericin B Lipid Complex@highlight

The purpose of this study is to determine if initial therapy with ABLC at 10/mg/kg/d for 7 days are at least effective as ABLC at 5.

0 mg/kg/d X 14 days as induction treatment of patients with disseminated cryptococcosis and HIV.

